Novavax Secures Additional $147M From Warp Speed Program For COVID-19 Vaccine

According to an SEC filing, Novavax Inc (NASDAQ: NVAX) has received an additional $147.3M as part of Operation Warp Speed to develop a COVID-19 vaccine dubbed NVX-CoV2373.
This addition brings its total from the program to $1.74 billion, which was announced in July last year.
President Joe Biden directly mentioned the company earlier this week, saying that upcoming vaccines, including one from Novavax, could be shared with other countries.
Early data out this year showed its vaccine could keep up in efficacy terms with the vaccine leaders, namely Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA).
While behind in authorizations compared to its rivals, which also now include AstraZeneca Plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) (though both have been hit recently with some safety concerns), with the rise of variants and outbreaks in highly populated places like Brazil and India, it still has a place globally to deliver billions of doses.
Price Action: NVAX shares are up 1.09% at $240.13 during the market session on the last check Friday.